Collegium Announces FDA Advisory Committee Meeting for Xtampza(TM) ER, an Abuse-Deterrent Analgesic for Chronic Pain
August 07, 2015 08:45 ET
|
Collegium Pharmaceutical
CANTON, Mass., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and...
Collegium Added to Russell 2000(R), 3000(R) and Global Indexes
July 06, 2015 16:15 ET
|
Collegium Pharmaceutical
CANTON, Mass., July 6, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Global Indexes...
Collegium Expands Leadership Team With Vice President of Regulatory Affairs and Quality Assurance
July 01, 2015 08:30 ET
|
Collegium Pharmaceutical
CANTON, Mass., July 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that John (Jack) Weet, Ph.D., has joined the company as its Vice President of Regulatory...
Collegium Announces Publication of "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations With Abuse-Deterrent Properties," in Pain Medicine
June 25, 2015 08:15 ET
|
Collegium Pharmaceutical
CANTON, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of a comparative clinical trial titled "Comparing the Effect of Tampering...
Collegium to Present Xtampza ER(TM) Oral Human Abuse Potential Data at the College on Problems of Drug Dependence 77th Annual Meeting
June 15, 2015 08:15 ET
|
Collegium Pharmaceutical
CANTON, Mass., June 15, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the presentation of a scientific poster at the College on Problems of Drug Dependence 77th...
Collegium Announces Issuance of U.S. Patent Covering DETERx(R) - an Abuse-Deterrent, Extended-Release Technology Platform
June 08, 2015 08:00 ET
|
Collegium Pharmaceutical
CANTON, Mass., June 8, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,044,398 was issued by the U.S. Patent and Trademark Office (USPTO)...
Collegium Expands Commercial Organization With Key Appointments
June 01, 2015 06:30 ET
|
Collegium Pharmaceutical
CANTON, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the addition of Barry Duke as Executive Vice President and Chief Commercial Officer. In...
Collegium to Present at the Jefferies 2015 Global Healthcare Conference
May 27, 2015 07:12 ET
|
Collegium Pharmaceutical
CANTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company's Chairman and CEO, Michael Heffernan, will present at the Jefferies 2015...
Collegium Pharmaceutical Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
May 12, 2015 16:05 ET
|
Collegium Pharmaceutical
CANTON, Mass., May 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the closing of its initial public offering of 6,670,000 shares of its common stock at a...
Collegium Pharmaceutical Announces Pricing of Its Initial Public Offering
May 07, 2015 07:45 ET
|
Collegium Pharmaceutical
CANTON, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., (Nasdaq:COLL) today announced the pricing of its initial public offering of 5,800,000 shares of its common stock at a...